Crossmark

Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature

Crossref DOI link: https://doi.org/10.1186/s40425-019-0803-x

Published Online: 2019-11-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Carausu, Marcela

Beddok, Arnaud

Langer, Adriana

Girard, Nicolas

Bidard, François-Clément

Massiani, Marie-Ange

Ricard, Damien

Cabel, Luc http://orcid.org/0000-0001-5515-9180
License Information

Text and Data Mining valid from 2019-11-21
More Information

Article History

Received: 2 September 2019

Accepted: 31 October 2019

First Online: 21 November 2019

Ethics approval and consent to participate

: Not applicable.

: Consent for publication was obtained from the patient.

: NG reports fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Roche/Genentech, and AstraZeneca for consultancy, travel, research outside the submitted work. The remaining authors declare that they have no competing interests.

Document is current

Any future updates will be listed below